Jentadueto FDA Approved Drugs
JENTADUETO [LinagliptinC25H28N8O2 : Metformin HydrochlorideC4H11N5ClH]
RX
- 2.5mg : 1gm (oral tablet)
2.5mg : 500mg (oral tablet)
2.5mg : 850mg (oral tablet)
Boehringer IngelheimJan 30, 2012
- Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin.
- Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea.
- Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
- Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin.
JENTADUETO XR [LinagliptinC25H28N8O2 : Metformin HydrochlorideC4H11N5ClH]
RX
- 2.5mg : 1gm (oral tablet, extended release)
Boehringer IngelheimMay 27, 2016
- Method of treating type 2 diabetes in patients who have not been previously treated with an antihyperglycemic agent by administering linagliptin in combination with metformin.
- Method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination with metformin.
- Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and, optionally, a sulfonylurea.
- Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin.
- Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
- Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin.
- Method of treating type 2 diabetes.
WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.